诺和诺德官宣!减重版司美格鲁肽在国内上市
稀土掘金
发表于 2024-11-18 10:49:53
176
0
0
减重药物的消费属性强,主要靠个人支付,受医保影响小。安信国际认为,鉴于今年已有两款进口减肥药在国内获批上市,中国减肥市场有望迎来高速增长阶段,或可关注GLP-1减肥产业链相关标的。
相关ETF:恒生医药ETF(159892)、生物科技ETF(516500)
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.